23 November 2015
The Chinese government has embarked on an unprecedented anti-corruption campaign for the past two years. This increase in enforcement activity, coupled with new and amended anti-corruption rules, has led to improved compliance practices for many foreign companies and their affiliates in China (PRC). This article examines the impact of the surge in enforcement actions, particularly the GlaxoSmithKline (GSK) investigation and decision. It also provides a series of steps that can be taken in developing an appropriate corporate compliance strategy in China.